Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04596579 · ClinicalTrials.gov registry record
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
A clinical trial, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- 1,135
- Enrollment target
NCT04596579 is a clinical trial that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 1,135 participants.
The verdict
NCT04596579 has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- 1,135 participants
- Enrollment target
Study Summary
The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.
Interventions
- DIAGNOSTIC_TEST SARS-CoV-2 Antibody Analysis
- DIAGNOSTIC_TEST Weck-cel Swab Collection
- BEHAVIORAL Web Based Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,135 participants |
| Start Date | 2020-10-17 |
| Est. Completion | 2021-07-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04596579
The ClinicalTrials.gov registry entry for NCT04596579 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SARS-CoV-2 Antibody Analysis is the first listed.
NCT04596579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04596579 about?
NCT04596579 is a clinical study titled "SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida". The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodie...
What is the current status of trial NCT04596579?
This trial is currently completed. The enrollment target is 1,135 participants. The study started on 2020-10-17. Estimated completion is 2021-07-25.
What interventions are being tested in trial NCT04596579?
The interventions under investigation include: SARS-CoV-2 Antibody Analysis (DIAGNOSTIC_TEST), Weck-cel Swab Collection (DIAGNOSTIC_TEST), Web Based Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT04596579?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.